Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort (original ) (raw )Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters
Suely Tuboi
AIDS, 2003
View PDFchevron_right
A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus Infection
David Cohn
New England Journal of Medicine, 1994
View PDFchevron_right
Rapid initiation of antiretroviral therapy for people living with HIV
Alberto mateo urdiales
Cochrane Database of Systematic Reviews, 2018
View PDFchevron_right
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK
Dimitrios Paraskevis
Journal of the International AIDS Society
View PDFchevron_right
Prospective Randomized Trial of Emtricitabine versus Lamivudine Short‐Term Monotherapy in Human Immunodeficiency Virus–Infected Patients
Ian Sanne
The Journal of Infectious Diseases, 2003
View PDFchevron_right
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS
Asabo Samuel
Reviews, 2013
View PDFchevron_right
Efficacy of 1998 Vs 2006 first-line antiretroviral regimens for HIV infection: An ordinary clinics retrospective investigation
Giovanni Pellicanò
2012
View PDFchevron_right
Didanosine, Lamivudine, and Efavirenz versus Zidovudine, Lamivudine, and Efavirenz for the Initial Treatment of HIV Type 1 Infection: Final Analysis (48 Weeks) of a Prospective, Randomized, Noninferiority Clinical Trial, GESIDA 3903
Juan Berenguer Berenguer
Clinical Infectious Diseases, 2008
View PDFchevron_right
Predictors of short-term success of antiretroviral therapy in HIV infection
Dieter Häussinger
Journal of Antimicrobial Chemotherapy, 2006
View PDFchevron_right
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a …
Enric Pedrol
Clinical Infectious …, 2008
View PDFchevron_right
Mortality and progression to AIDS after starting highly active antiretroviral therapy
Peter Reiss
AIDS, 2003
View PDFchevron_right
HIV management in practice
Theresa Rossouw
Continuing Medical Education, 2011
View PDFchevron_right
of HIV-infected patients from the
Pompeyo Viciana
2015
View PDFchevron_right
Reomendaciones Recientes Para el Manejo de PACIENTES HIV
Karen Sanchez
View PDFchevron_right
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings
Ruben Lopez
PLoS Medicine, 2012
View PDFchevron_right
HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico
Laine Pinto
Journal of the International AIDS Society, 2015
View PDFchevron_right
Treatment of AIDS and HIV- Related Conditions: 2000
Betty Dong
Journal of the American Board of Family Medicine, 2000
View PDFchevron_right
Use of Highly Active Antiretroviral Therapy in a Cohort of HIV-Seropositive Women
Lytt Gardner
American Journal of Public Health, 2002
View PDFchevron_right
Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the Caribbean
Suely Tuboi
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
View PDFchevron_right
A Proof‐of‐Concept Study of Short‐Cycle Intermittent Antiretroviral Therapy with a Once‐Daily Regimen of Didanosine, Lamivudine, and Efavirenz for the Treatment of Chronic HIV Infection
April Powers
The Journal of Infectious Diseases, 2004
View PDFchevron_right
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting
Dolorès Vaira
AIDS, 2014
View PDFchevron_right
Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy
Catherine O'Connor
PLoS ONE, 2012
View PDFchevron_right
Short-Course Antiretroviral Therapy in Primary HIV Infection
Mauro Schechter
New England Journal of Medicine, 2013
View PDFchevron_right
Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz
Joseph Okopi
GERMS, 2015
View PDFchevron_right
Treatment of AIDS and HIV-Related Conditions-1999
Betty Dong
Journal of the American Board of Family Medicine, 1999
View PDFchevron_right
Drug-Resistant HIV Infection among Drug-Naive Patients in Israel
Dina Averbuch
Clinical Infectious Diseases, 2005
View PDFchevron_right
Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
Valerie Stone
Clinical Infectious Diseases, 2004
View PDFchevron_right
Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
Jean-michel Livrozet
Journal of the International AIDS Society, 2010
View PDFchevron_right